Before revision:  We  constructed our protocol against a molecular region in the N-terminal domain of SARS-CoV-2 Spike protein, already experimentally identified in interaction with antibodies in humans.
After revision:  We thus constructed our protocol against a molecular region in the N-terminal domain of SARS-CoV-2 Spike protein, already experimentally identified in interaction with antibodies in humans.